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Objectives: The clinical results of Carpentier-Edwards standard bioprosthesis have
been extensively studied for valvular heart surgery in America and Europe. How-
ever, the data of long-term performance of Carpentier-Edwards standard porcine
valve in areas with a high prevalence of rheumatic heart disease are still lacking. In
this study, we assessed the clinical performance of Carpentier-Edwards standard
porcine bioprostheses in a patient group with high prevalence of rheumatic heart
disease.
Methods: A total of 872 patients underwent valvular heart surgery with Carpentier-
Edwards standard porcine bioprostheses replacement between 1975 and 1999 and
the results were analyzed. Rheumatic etiology counts for 95% of the patients. Mean
age of operation was 40 14 years (mitral valve), 43 19 years (aortic valve), and
45  13 years (double valve). Follow-up was 95.6% complete and continued up to
24 years (total 7017 patient-years) with mean of 8.9  5.1 years.
Results: The operative mortality rate was 5.85%. Actuarial patient survival rates
after discharge at 5, 10, 15, and 20 years were 92.5%, 83.8%, 72.3%, and 35.8%,
respectively. A total of 442 cases received reoperation due to failure of bioprosthe-
ses. The mean duration to valve failure is 12.2  0.4 years. Actuarial estimate of
freedom from structural valvular failure at 5, 10, 15, and 20 years were 96.3%,
63.7%, 24.4%, and 7.7%, respectively.
Conclusion: The long-term result of Carpentier-Edwards standard bioprostheses in
the present patient group is satisfactory. However, freedom from valve failure is
lower than that of Western series. Younger age at operation and higher prevalence
of rheumatic etiology in this area are possible causes.
The clinical experience reported in recent Western series has providedvaluable information with regard to the structural durability andvalve-related complications of biological valve substitutes.1-4Younger age at operation is a significant risk factor for structuralvalve deterioration and reoperation.4 The freedom from structuralvalvular dysfunction of Carpentier-Edwards (CES) porcine biopros-
thesis has been reported to range from 70.8% to 87.0% at 10 years.1-3 However, the
data of long-term performance of CES porcine valve in an area where rheumatic
heart disease prevails is still lacking. Rheumatic heart disease has been endemic
disease in Asian developing countries for the past 30 years.5,6 Therefore rheumatic
valvular dysfunction was the major disease category for operation with CES valve
in this area. We hypothesized that the clinical performance of CES bioprosthesis in
Southeast Asia might be different from that of Western countries due to different
etiology of operation. We conducted the present study to assess and follow up those
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patients undergoing valvular replacement with CES porcine
valves. This study was designed to (1) evaluate the effect of
age on patient survival, (2) assess the freedom from valve
failure, and (3) evaluate the effect of valve site on patient
survival and structural valvular failure.
Materials and Methods
Patients
CES porcine bioprostheses were implanted in 872 patients (1060
bioprostheses) from 1975 to 1999 in a single hospital (Figure 1).
Supra-annular–type bioprostheses were not available until 2000 in
our country; all the bioprostheses in this study were standard type
[model 2625(A) and 6625(M)]). Over 90% of those operations
were performed between 1977 and 1984. Operations were per-
formed mainly by 6 doctors. Ninety-five percent were rheumatic
heart disease in nature. Rheumatic heart disease was diagnosed
from clinical history and serological and echocardiographic stud-
ies, as well as pathological findings. The operation was performed
through median sternotomy with standard cardiopulmonary bypass
and cardioplegic cardiac arrest. The cardioplegic solution was
self-formulated solution before early 1980, commercialized solu-
tion (St Thomas Hospital solution) from early 1980 to 1990, and
cold blood cardioplegia after 1990. CES porcine bioprosthesis was
irrigated thoroughly before implantation to remove preservative
solution. Suturing was performed with interrupted 2-0 Ticron in
eversion technique with Teflon plegets or multiple single stitches
without pledgets, according to operators’ preference. During fol-
low-up in outpatient clinics, anticoagulant therapy with warfarin
(prothrombin time was controlled at 1.5 to 2 times of control
value) was prescribed for a 3-month course except for patients
with atrial fibrillation with large atrium or patients with history of
emboli, who needed longer anticoagulant therapy.7
Follow-up
Follow-up was conducted retrospectively by chart review (in
78%), patient investigation (14.8%), and telephone/mail follow-up
(6.6%). Operative mortality included any cardiac death that oc-
curred within 30 days after the operation or before hospital dis-
charge. Late mortality included any cardiac death that occurred
during the follow-up period. Valve-related events were categorized
in accordance with the guideline for reporting morbidity and
mortality devised by the American Association of Thoracic Sur-
gery and the Society of Thoracic Surgeons ad hoc committee.8
Structural valve failure was diagnosed and documented by clinical
Figure 1. Individual cases in the present study, plotted against
operative year and age.
TABLE 1. Cause of early and late mortality
Cause Mortality numbers (%)
Early
Congestive heart failure 25 (2.87)
Intractable arrhythmia 6 (0.69)
Bleeding 4 (0.46)
Stroke 3 (0.34)
Infection 2 (0.23)
Renal failure 4 (0.46)
Respiratory failure 7 (0.80)
Total 51 (5.85)
Late
Acute myocardial infarct 6 (0.69)
Stroke 16 (1.83)
Congestive heart failure 73 (8.37)
Ventricular arrhythmia 3 (0.34)
Sudden death 3 (0.34)
Sepsis 7 (0.80)
Noncardiac cause 33 (3.78)
Unknown 13 (1.49)
Total 154 (17.66)
Figure 2A. Actuarial survival after CES bioprosthesis
implantation.
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presentation and reoperative findings8 before mid 1980 or by the
above criteria as well as echocardiographic study9 after mid 1980,
when we generalized 2-dimensional Doppler echocardiogram into
clinical use at our hospital.
Statistics
Data were expressed as mean standard deviation. Simple morbid
events were reported as a simple percentage. Time-related events
were reported as linearized rate (number of events divided by the
total patient-years) or plotted as Kaplan-Meier survival curve,
actuarial life table, or actual rate.10 Statistical comparison between
groups was computed by Student t test, chi-square test, or log-rank
test according to specific data type. P  .05 was considered
significant.
Results
Patients
There were 406 men (46.6%) and 466 women (53.4%).
There were 161 (18.5%) aortic valve replacements (AVR),
523 (60.0%) mitral valve replacements (MVR), and 188
(21.6%) both aortic and mitral valve replacements (DVR).
The ages ranged from 9 to 81 years; mean age at operation
was 40  14 (MVR), 43  19 years (AVR), and 45  13
Figure 2B. Effects of valve site on survival after CES bioprosthesis implantation.
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(DVR). The total follow-up was 95.6% complete during the
6-month closing interval before our study period. The total
cumulative follow-up was 7017 patient-years, with mean of
8.94  5.08 years.
Patient Survival
The overall operative mortality was 5.85% (51 of 872
patients). As divided by decades, the operative mortality
rate were 6.36%, 6.28%, and 0.00% in the periods before
1980, between 1980 and 1990, and after 1990, respectively.
The overall late mortality was 154 of 785 cases (2.19% per
patient-year). The causes of early and late mortality are
listed in Table 1. The actuarial survival rate of all dis-
charged cases at 5, 10, 15, and 20 years were 92.5%, 83.8%,
72.3%, and 35.8%, respectively (Figure 2, A). The survival
rate of patients receiving DVR was initially similar to that
of single valve replacement but became worse than that of
patients receiving either MVR or AVR at about 8 years after
operation (P  .03 and P  .01; respectively, Figure 2, B).
Patients younger than 40 years had better survival curve
than those older than 40 years (Figure 2, C). Both sexes had
similar survival curves (P  .21).
Structural Valve Failure
During the follow-up period, 442 cases (56.3%) received
reoperation due to bioprostheses failure. The linearized rate
was 6.30 per patient-year. The predominant pathology at
reoperation of explanted valve was calcification on the
leaflets, making the leaflets thickened and fused. Another
major finding was linear tear of the leaflet, which was
Figure 2C. Survival after CES bioprosthesis implantation according to age younger or older than 40 years.
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usually associated with valve incompetence. Occasionally,
perforation holes in the leaflets were found, in patients for
whom history of prosthetic valve endocarditis (PVE) some-
times could be traced. The mean duration to valve failure is
12.2 0.4 years. Actuarial freedom rates from valve failure
at 5, 10, 15, and 20 years were 96.3%, 63.7%, 24.4%, and
7.7%; respectively (Figure 3, A). Actual rate of freedom
from reoperation was also plotted (Figure 4). These 2 meth-
ods began to show differences only after 10 years because
of the relatively small number of mortality of valve failure
cases. Male and female patients had similar freedom from
valve failure rates (P  .80). The patients were subgrouped
as (1) 60 years, (2) between 40 and 60 years, (3) between
20 and 40 years, and (4) 20 years. The median valve
survival duration was 13.08, 12.30, 11.96, and 10.86 years
in groups 1, 2, 3, and 4, respectively (Figure 3, B). Only
groups 1 and 4 were statistically significant (P  .03).
Valvular sites (mitral, aortic, and both) also affected the
mean survival duration of CES porcine bioprostheses (Fig-
ure 3, C). Mean survival duration of DVR (11.07 years) was
worse than either AVR (12.26 years; P  .003) or MVR
(11.96 years; P  .03). Whether warfarin was used did not
influence freedom from valve failure rate (P  .29). Free-
dom from reoperation rate among valves replaced before
1980 was not different from those replaced after 1980 (P 
.11; Figure 3, D).
Discussion
Patient Survival
The present study documented better survival and worse
freedom from valve failure rate in our patient group than
several published big series.1-4 Age difference is the most
possible cause. Long-term actuarial survival estimates at 5,
10, and 15 years have been reported by Fann and col-
leagues4 to be 77  1%, 54  2%, and 32  3%, respec-
tively, for the AVR with porcine bioprosthesis (Hancock
valve) and respective rates for MVR were 70  1%, 50 
2%, and 32  3%. Similar data have also been reported by
Fiane and colleagues,11 whose actuarial survival rates at 5
and 10 years were 73.2  5.2% and 52.1  6.6% for AVR
with CES bioprosthesis and 76.7  4.2% and 61.6  4.8%
for MVR. In the present study, long-term actuarial survival
estimates at 5, 10, and 15 years were 94.4%, 88.5%, and
82.7%, respectively, for AVR and the respective rates for
MVR are 91.6%, 88.5%, and 82.7%. The mean age of
patients in the present study is younger than those of other
studies [40  14 years (MVR) and 43  19 years (AVR),
Table 2]. In the data reported by Fann and coworkers,4 the
Figure 3A. Actuarial survival curve for freedom from valve failure needing reoperation.
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mean age at operation was 58  13 years (MVR) and 60 
15 years (AVR). The age discrepancy between this report
and that of other major series can be attributed to the
etiology of valvular heart disease. In our hospital, most of
the patients (95%) underwent valvular replacement at that
time due to rheumatic origin,12 while rheumatic disease
only accounts for 47% in Western series.1 This cohort of
younger rheumatic patients is also documented by other
series, such as John and colleagues and Duran and cowork-
ers,13,14 both of which were also based on patients of
rheumatic etiology. The main reasons for the high preva-
lence rate of rheumatic fever and rheumatic heart disease in
these Asian areas are subtropic climate, crowded popula-
tion, and poor economic status at that time, as well as
prevalence of streptococcal infections.15
By analyzing respective perioperative mortality rates in 3
separate decades (before 1980: 6.36%, 1980 to 1990:
6.28%, and after 1990: 0.00%), no differences of operative
outcome could be found between self-formulated or com-
mercialized cardioplegic solution (separated by early 1980),
Figure 3B. Actuarial survival curve of freedom from valve failure, grouped by age.
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while marked improvement could be found after 1990, due
to advance in operative technique, cardiopulmonary bypass,
and myocardial protection, as well as intensive care unit and
ward nursing techniques.
Structural Valve Dysfunction
On the other hand, age was discovered to be a significant risk
factor for primary tissue failure of bioprosthesis by many
authors.4,9 In the present report, our data were compatible with
those series, either by actuarial or actual rate. The mean age of
operation was younger in this study, which could explain why
the freedom from structural valvular dysfunction is lower than
those of the Western series (Table 2).
To compare structural valve failure rate in specific age
groups, we picked out a subgroup of 40 to 50 years old with
either MVR (n  121) or AVR (n  22) to study. In MVR
cases, the freedom from structural valve failure at 5, 10, 15,
and 20 years are 99.1  0.9%, 63.1  5.1%, 16.6  4.3%,
and 13.3  4.0%, respectively, which are quite similar to
that reported by Fann and colleagues4 (97%, 65%, 21% at 5,
10, 15 years, respectively) and by Jamieson and colleagues2
(12% and 0% at 15 and 20 years, respectively) for the same
age MVR subgroup. In AVR cases, the freedom from struc-
tural valve failure at 5, 10, 15, and 20 years are 100 0.0%,
80  10%, 44  13%, and 7.5  7%, respectively, which
are also similar to that reported by Fann and colleagues4
(100%, 70%, 47% at 5, 10, 15 years, respectively) and by
Jamieson and coworkers2 (42% and 26%, at 15 and 20
years, respectively) for the same age subgroup with AVR.
This finding suggests age to be an important determining
factor of structural valve failure in both the West and the
East.
The high prevalence of rheumatic heart disease may
partially explain the progression of structural valve dysfunc-
tion, which was supported indirectly by the pathology of
explanted valves (calcification, linear tear, and perforation).
Valvular sites (mitral, aortic, or both) also affected the mean
Figure 3C. Actuarial survival curve of freedom from valve failure, grouped by valve implantation sites in mitral or
aortic sites.
Surgery for Acquired Cardiovascular Disease Yu et al
86 The Journal of Thoracic and Cardiovascular Surgery ● July 2003
A
CD
survival duration of CES porcine bioprostheses in this
study. Mean rates durability of AVR (12.26 years), MVR
(11.96 years), and DVR (11.07 years) were better than those
reported by Bernal and colleagues16 (92.9 months for AVR,
101.6 months for MVR, 84.3 months for DVR).
Later year of operation had higher rate of structural valve
dysfunction in our data (Figure 3, D), which is compatible
with that reported by Fann and colleagues.4 One possible
explanation is the early detection of structural valve dys-
function with improved technology. The 2-dimensional
Doppler echocardiography was generalized in our hospital
since mid 1980, so many of the patients in the first time
period (1975 to 1980) could not be followed by this
method. Besides this, it also implies that structural valve
failure rate is not inversely related to economic status.
(Gross national income in Taiwan at 1976 to 1979 and
1980 to 1985 were 850 and 1846 New Taiwan Dollar,
respectively.)
Limitations
Much of our data was collected before 1996, when Ed-
munds and colleagues8 published the guideline for reporting
the long-term results of valvular surgery; some of our pa-
rameters might not be wholly the same with suggested
formats.
Another limitation is that because 95% of our cases were
rheumatic in nature, no sufficient nonrheumatic cases can be
compared to elucidate whether disease nature is one factor
influencing structural valve dysfunction rate.
Another limitation is homogenicity of valves used in our
hospital (CES),7 so no comparison can be made with other
major types of first- or second-generation bioprostheses
with respect to the durability of different valves in rheu-
matic patients.
The other limitation is the young age group in our early
operation population (Figure 1). This means most patients
older than 60 years were censored at less than 5 years, so we
Figure 3D. Survival curve of freedom from valve failure, grouped by valve replaced before or after 1980.
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cannot obtain reliable CES reoperation rate in that age
group. This is one possible explanation why structural val-
vular failure rate of AVR in the present study is higher than
that by other reports.
Conclusions
The long-term results of CES bioprostheses in this patient
group are satisfactory. However, freedom from valve failure
is lower than that of Western series. These differences are
due to younger age at operation and higher prevalence of
rheumatic etiology in this area.
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